MEP35908A - Treatment of hypertension in women receiving hormone replacement therapy - Google Patents

Treatment of hypertension in women receiving hormone replacement therapy

Info

Publication number
MEP35908A
MEP35908A MEP-359/08A MEP35908A MEP35908A ME P35908 A MEP35908 A ME P35908A ME P35908 A MEP35908 A ME P35908A ME P35908 A MEP35908 A ME P35908A
Authority
ME
Montenegro
Prior art keywords
replacement therapy
hormone replacement
hypertension
treatment
women receiving
Prior art date
Application number
MEP-359/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Adel H Karara
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MEP35908A publication Critical patent/MEP35908A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/553—Renin inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-359/08A 2002-04-26 2003-03-24 Treatment of hypertension in women receiving hormone replacement therapy MEP35908A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37543902P 2002-04-26 2002-04-26
PCT/US2003/012596 WO2003090755A1 (en) 2002-04-26 2003-03-24 Treatment of hypertension in women receiving hormone replacement therapy

Publications (1)

Publication Number Publication Date
MEP35908A true MEP35908A (en) 2011-02-10

Family

ID=29270642

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-359/08A MEP35908A (en) 2002-04-26 2003-03-24 Treatment of hypertension in women receiving hormone replacement therapy

Country Status (23)

Country Link
US (1) US20040034001A1 (ko)
EP (2) EP1982719A1 (ko)
JP (1) JP2005528408A (ko)
KR (1) KR20040104632A (ko)
CN (1) CN1649596A (ko)
AU (2) AU2003239162A1 (ko)
BR (1) BR0309780A (ko)
CA (1) CA2483554A1 (ko)
CR (1) CR7571A (ko)
EC (1) ECSP045456A (ko)
HK (1) HK1079997A1 (ko)
HR (1) HRP20041121A2 (ko)
IL (1) IL164808A0 (ko)
ME (1) MEP35908A (ko)
MX (1) MXPA04010682A (ko)
NO (1) NO20045147L (ko)
NZ (1) NZ548754A (ko)
PL (1) PL372055A1 (ko)
RS (1) RS93804A (ko)
RU (1) RU2373940C2 (ko)
UA (1) UA87437C2 (ko)
WO (1) WO2003090755A1 (ko)
ZA (1) ZA200409548B (ko)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
DE102004016779A1 (de) * 2004-04-01 2006-01-19 Schering Ag Drospirenonhaltige Zubereitungen zur transdermalen Anwendung
ATE493973T1 (de) 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
US20070275941A1 (en) * 2006-05-17 2007-11-29 Vladimir Hanes Salt sensitivity and prevention of hypertension with drospirenone
US20090035374A1 (en) * 2007-07-31 2009-02-05 Katrin Mittmann Method of making a single-stage pharmaceutical preparation for oral therapy to regulate blood pressure and kit containing same
US20090035373A1 (en) * 2007-07-31 2009-02-05 Katrin Mittmann Pharmaceutical composition for contraception and blood pressure regulation, kit for contraception containing same and method of production of same
CA2795801C (en) * 2010-04-15 2018-05-29 Bayer Intellectual Property Gmbh Very low-dosed solid oral dosage forms for hrt
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
RU2648470C2 (ru) * 2016-03-03 2018-03-26 Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральский государственный медицинский университет Министерства здравоохранения Российской Федерации" (ГБОУ ВПО УГМУ Минздрава России) Способ оптимизации лечения женщин кардиотропной терапией и заместительной гормональной терапией при эстрогенодефиците с артериальной гипертензией в позднем репродуктивном периоде
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
US5001113A (en) 1987-10-14 1991-03-19 Merck & Co., Inc. Di- or tripeptide renin inhibitors containing lactam conformational restriction in ACHPA
US6300361B1 (en) 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
DE4344462C2 (de) * 1993-12-22 1996-02-01 Schering Ag Zusammensetzung für die Empfängnisverhütung
US6083528A (en) 1995-09-28 2000-07-04 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
US5922349A (en) * 1995-09-28 1999-07-13 Schering Aktiengesellschaft Hormone replacement therapy method and hormone dispenser
KR0156678B1 (ko) 1996-01-11 1998-10-15 이상윤 안지오텐신 전환효소 저해제
US5789442A (en) * 1996-01-18 1998-08-04 Schering Aktiengesellschaft Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
DE19633685C1 (de) 1996-08-12 1997-10-09 Schering Ag Verfahren zur Herstellung von Drospirenon (6beta,7beta;15 beta,16beta-Dimethyl-en-3-oxo-17alpha-pregn-4-en-21,17-carbolacton, DRSP) sowie 7alpha-(3-Hydroxy-1-propyl)-6beta,7beta;15beta, 16beta-dimethylen-5beta-androstan-3beta,5,17beta-triol (ZK 92836) und 6beta,7beta;15beta,16beta-dimethylen-5beta-hydroxy-3-oxo-17alpha-androstan-21,17-carbolacton (90965) als Zwischenprodukte des Verfahrens
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone
US20010056068A1 (en) * 1998-03-04 2001-12-27 Kristof Chwalisz Method of treatment and prevention of nitric oxide deficiency-related disorders with citrulline and citrulline derivatives
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
DK1598069T3 (da) * 1999-08-31 2009-07-06 Bayer Schering Pharma Ag Farmaceutisk præparat af ethinylestradiol og drospirenon til anvendelse som præventionsmiddel
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
PL201878B1 (pl) * 2000-01-18 2009-05-29 Bayer Schering Pharma Ag Kompozycja farmaceutyczna w doustnej postaci dawkowania. zawierająca estrogen i drospirenon, zastosowanie kompozycji i preparat farmaceutyczny
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
US20020111337A1 (en) * 2000-08-28 2002-08-15 Fedde Kenton N. Use of an aldosterone receptor antagonist to improve cognitive function
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins

Also Published As

Publication number Publication date
UA87437C2 (ru) 2009-07-27
ECSP045456A (es) 2005-01-28
KR20040104632A (ko) 2004-12-10
EP1499323A1 (en) 2005-01-26
NO20045147L (no) 2005-01-18
MXPA04010682A (es) 2004-12-13
EP1982719A1 (en) 2008-10-22
RS93804A (sr) 2006-10-27
US20040034001A1 (en) 2004-02-19
CN1649596A (zh) 2005-08-03
BR0309780A (pt) 2005-03-22
CA2483554A1 (en) 2003-11-06
AU2008203497A1 (en) 2008-08-28
JP2005528408A (ja) 2005-09-22
NZ548754A (en) 2008-06-30
RU2004134571A (ru) 2005-07-10
ZA200409548B (en) 2010-05-26
PL372055A1 (en) 2005-07-11
HK1079997A1 (zh) 2006-04-21
RU2373940C2 (ru) 2009-11-27
IL164808A0 (en) 2005-12-18
HRP20041121A2 (en) 2005-02-28
AU2003239162A1 (en) 2003-11-10
CR7571A (es) 2006-02-07
WO2003090755A1 (en) 2003-11-06

Similar Documents

Publication Publication Date Title
MEP35908A (en) Treatment of hypertension in women receiving hormone replacement therapy
HK1051005A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity
ATE412387T1 (de) Medizinische vorrichtungen
DE502008002148D1 (de) Arzneimittel umfassend wenigstens ein gestagen
HK1051324A1 (en) Methods and compositions for modulating alpha adrenergic receptor activity.
CR7610A (es) Uso de derivados de thio-oxindol en el tratamiento de condiciones realcionadas con la hormona
DE50313551D1 (de) Gefässprothese, insbesondere zum ersatz der aorta ascendens
HK1068261A1 (en) Combinations comprisinga selective cyclooxygenase-2 inhibitor
AU2003252131A1 (en) Uv-crosslinked, pressure-sensitive adhesives
NO20053626L (no) Blanding omfattende en kombinasjon av en aromataseinhibitor, et progestin og et ostrogen for anvendelse av behandling av endomeriose
WO2001062784A3 (en) Use of breast cancer associated membrane proteins (bcmp) for treatment, prophylaxis and diagnosis of breast cancer
AU5628800A (en) Substituted benzamide inhibitors of rhinovirus 3c protease
PE20050665A1 (es) ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
UY28017A1 (es) Tratamiento terapéutico
DK1635843T3 (da) Terapi, der omfatter dienogest for hormonerstatning og depression
RS37804A (en) Use of n,n-diethyl-2-/-4-(phenylmethyl)- phenoxy/ethanamine monohydrochloride (dppe)in cancer therapy
WO2003039455A3 (en) Methods of treating endometreosis
EE200400069A (et) Tsitalopraami kasutamine ravimkoostiste valmistamiseks kõrgenenud vererõhu raviks
AR039477A1 (es) Terapia de reemplazo hormonal
UA49495A (uk) Спосіб лікування переломів кісток
EA200100745A1 (ru) СПОСОБ ПОЛУЧЕНИЯ 6β,7β;15β,16β- ДИМЕТИЛЕН-5β-ГИДРОКСИ-3-ОКСО-17α-АНДРОСТАН-21,17-КАРБАЛАКТОНА
ATE268193T1 (de) Arzneimittel, enthaltend doxazosin-mesylat der kristallmodifikation d
UA31403A (uk) Спосіб забезпечення кровопостачання печінки при цирозі
RU99102645A (ru) Способ лечения микроинвазивного рака вульвы
UA43619A (uk) Бетатирон - пролонгований антигіпертензивний засіб нової генерації